Can peripheral blood be used to detect residual disease in acute lymphoblastic leukaemia (ALL) when we increase the sensitivity of the method used? Bendig et al. found that a larger amount of material and the use of next-generation sequencing (NGS) detects MRD in peripheral blood in up to half of patients with B-cell precursor ALL (BCP-ALL) where routine examination was negative. However, a negative result does not exclude the presence of residual disease and thus still limits the use of peripheral blood. Commentary on: Bendig et al. Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 2025; 206:353-356.

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

See more in PubMed

Bendig , et al. BJH.

van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans‐Bitter WM, Willemse MJ, Hahlen K, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor‐B‐ALL. Leukemia. 2002;16(8):1432–1436. PubMed

Muffly L, Liang EC, Dolan JG, Pulsipher MA. How I use next‐generation sequencing‐MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood. 2024;144(3):253–261. PubMed PMC

Bruggemann M, Kotrova M, Knecht H, Bartram J, Boudjogrha M, Bystry V, et al. Standardized next‐generation sequencing of immunoglobulin and T‐cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality‐NGS validation study. Leukemia. 2019;33(9):2241–2253. PubMed PMC

Kotrova M, Fronkova E, Svaton M, Drandi D, Schon F, Hoogeveen P, et al. The gray area of RQ‐PCR‐based measurable residual disease: subdividing the "positive, below quantitative range" category. Leukemia. 2024;38(7):1617–1620. PubMed PMC

van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, et al. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia. 2024;38(6):1315–1322. PubMed PMC

Svaton M, Skotnicova A, Reznickova L, Rennerova A, Valova T, Kotrova M, et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD‐based protocol. Blood. 2023;141(5):529–533. PubMed PMC